Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 9/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22984011 | 1.00 | STING1 (0.44) | STING1PDE3BPDE3ATAS1R3TAS1R1 | |
| SCHEMBL25504663 | 1.00 | STING1 (0.44) | STING1PDE3BPDE3ATAS1R3TAS1R1 | |
| SCHEMBL19491649 | 1.00 | STING1 (0.44) | STING1PDE3BPDE3ATAS1R3TAS1R1 | |
| SCHEMBL19880310 | 0.88 | KDM4E (0.47) | STING1PDE3BPDE3ATAS1R3TAS1R1 | |
| SCHEMBL19509409 | 0.88 | KDM4E (0.47) | STING1PDE3BPDE3ATAS1R3TAS1R1 | |
| SCHEMBL25496217 | 0.88 | KDM4E (0.47) | STING1PDE3BPDE3ATAS1R3TAS1R1 | |
| SCHEMBL10457794 | 0.88 | KDM4E (0.47) | STING1PDE3BPDE3ATAS1R3TAS1R1 | |
| SCHEMBL18954971 | 0.88 | KDM4E (0.47) | STING1PDE3BPDE3ATAS1R3TAS1R1 | |
| SCHEMBL1936920 | 0.88 | KDM4E (0.47) | STING1PDE3BPDE3ATAS1R3TAS1R1 | |
| SCHEMBL19502688 | 0.87 | TAS1R3 (0.46) | STING1PDE3BPDE3ATAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249173-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140255339-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-7951789-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140255339-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, GYS2 | STING1 202/4885PDE3B 1389/4885PDE3A 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.